Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 2007

View Archived Issues

Phase I clinical study of DC/Apo-Nec melanoma vaccine

Newly formed Altair focuses on therapy for respiratory conditions

Cubist obtains option to acquire Illumigen

Omrix's fibrin patch demonstrates safety in phase I

Savient makes progress in phase III trial of Puricase for treatment-failure gout

DSMB recommends continuation of phase III Medidur trial

Dara BioSciences and Bayer sign metabolic disease alliance

Innocoll files IND for CollaRx bupivacaine topical

Novel anti-Helicobacter pylori agents imparted in recent aRigen patent

Agreement to develop Erbitux for mCRC in Japan

Phase I trial commences for Lu-AA-24493 in acute ischemic stroke

Ampakine molecules could be useful in treating Rett syndrome / News in Context

In vivo antitumor activity of meriolin-3, a novel CDK inhibitor

Careload receives marketing approval in Japan for PAH

New treatment options for inflammatory disorders disclosed in recent patents

Implicit awarded U.S. government contract for biodefense drug

Abbott and Solvay sign Simcor copromotion agreement in U.S.

Levemir approved in Japan for type 1 and 2 diabetes

Plavix sNDA approved to include acute coronary syndrome patients in Japan

Tarceva approved for lung cancer patients in Japan

Kissei Pharmaceutical receives approval in Japan for additional indication of Salagen

Mochida Pharmaceutical receives approval in Japan for Dinagest for endometriosis

Taxotere receives positive opinion in the E.U. for head and neck cancer

Recent patents describe novel antipsychotic agents

Voltaren gel receives U.S. regulatory approval for osteoarthritis pain

FDA issues approvable letter for telavancin in cSSSIs

Renvela receives FDA approval for dialysis patients

Escitalopram could be effective for the treatment of premature ejaculation / News in Context

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026